Business
Bionano Announces Presentations at the American Society of Hematology (ASH) Annual Meeting that Underscore OGM Utility Across Blood Cancer Research and Cell & Gene Therapy
Thirteen scientific posters feature results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS),
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"Thirteen scientific posters feature results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), lymphoma, and other hematological malignancy research will be presented at the conferenceThree of the 13 posters were selected to be presented in two sessions dedicated to “Acute Myeloid Leukemias (AML): Biomarkers and Molecular Markers in Diagnosis and Prognosis” and “Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis”Additional poster feature application of OGM in bioprocessing quality control (QC) for analysis of CRISPR/Cas edited cells for use in CAR-T therapy SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that the American Society of Hematology (ASH) Annual Meeting and Exposition 2024 will feature a broad range of content covering OGM’s utility for research in areas including myeloid cancer, hematological malignancy, leukemia and blood disorders. ASH’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in the field of blood disease. The ASH conference is being held December 7-10, 2024, in San Diego, California and online. Thirteen posters featuring results from OGM applications in cytogenomic research will be presented at the conference. Three of the 13 posters were presented in sessions dedicated towards AML (posters 1538 and 1539) and ALL (poster 4224) clinical research applications. Posters displayed at the conference may also be viewed here; online only posters may be viewed here. Scientific presentations and poster sessions from Bionano and collaborators include: PosterTitleAuthorPresentedOnline PublicationNovel Tools to Improve the Challenging Diagnosis of Ph-like ALL. Comparison between Optical Genome Mapping and Digital-MLPAGianfranco Lapietra (University of Rome).1559Optical Genome Mapping Reclassifies Patients with Intermediate Risk Acute Myeloid LeukemiaBaher Krayem (Rambam Health Care Campus)December 7, 2024: 5:30-7:30 PMOnline PublicationCan Optical Genome Mapping Replace Bone Marrow Biopsies in Acute Myeloid Leukemia?Logan Hahn, John DeCoteau, Karen Mochoruk, Gabriela Tanumihardja,Logan Hahn (University of Saskatchewan).Online PublicationOptical Genome Mapping in Newly Diagnosed Chronic Lymphocyt...